MacuHealth PLUS+(90 Days Supply)
- EYE VITAMINS FOR MACULAR DEGENERATION: Whether youre at risk for macular degeneration or have already been diagnosed with it, you want to do everything possible to improve your ocular health. MacuHealth PLUS+ eye vitamins for macular degeneration help rebuild macular pigment over your lifetime.
- MACUHEALTH EYE VITAMIN WITH LMZ3: The patented macular health carotenoids formula is designed to improve macular pigment over time: our eye vitamins 10:10:2 ratio of Lutein (10mg), Meso-Zeaxanthin (10mg), and Zeaxanthin (2mg) is proven through peer-reviewed research to rebuild macular pigment.
- IMPROVES VISION AND EYE HEALTH: Consistent use of MacuHealth PLUS+ is shown to improve vision clarity and performance by protecting your eyes from blue light, decrease inflammation of the retina, and help control and reverse macular degeneration.
- THE MACUHEALTH PLUS+ DIFFERENCE: Our PLUS+ formula contains vitamin C, vitamin E, zinc, copper, and the full range of macular pigments. Its based on the extensive AREDS2 trial results, with zinc levels reduced to safe amounts.
Vitamins for Macular Degeneration Based on the AREDS2 study MacuHealth PLUS+ is specifically formulated by eye health experts for those patients already diagnosed with age-related macular degeneration. AREDS2 was published in 2013. Here is what they found: AREDS2 demonstrated a statistically significant reduction of 9% in risk of disease progression to advanced AMD for patients receiving two of the three macular carotenoids (lutein and zeaxanthin) when compared with patients not receiving these antioxidants. The reduction in concentration of zinc from 80mg to 25mg (as found in MacuHealth PLUS+) did not have an adverse effect on the desirable and observed reduced risk of progression to advanced AMD. MacuHealth PLUS+ = AREDS2 formulation, with two important distinctions, as follows: Reduced Zinc from 80mg to 25mg, thereby compliant with RDA (recommended dietary allowance) and therefore precluding the possibility of any increased risk for disease progression in AMD patients with a particular genetic background. Of note, AREDS2 has shown that there was no significant difference between the AMD group who received 25mg of zinc compared to the AMD group who received 80mg of zinc (in terms of benefits), supporting further the decision to recommend a lower (25mg) zinc dose for patients with AMD. The addition of 10mg of Meso-Zeaxanthin (the third and centrally dominant macular carotenoid), thereby facilitating maximum augmentation of macular pigment and facilitating optimization of visual performance in eyes with AMD. The evidence base for supplementation in patients with AMD favors an AREDS2 formulation, but without dangerous levels of Zinc, and using a supplement that contains all three macular carotenoids in a MZ:L:Z (mg) ratio of 10:10:2. The only such commercially available supplement is MacuHealthPLUS+. AREDS2 is a registered trademark of the United States Department of Health and Human Services (HHS)